Abstract
In The Lancet Infectious Diseases, Sarah Prentice and colleagues1 report that the tuberculosis vaccine BCG protects against non-tuberculous infectious diseases. In a randomised controlled trial (RCT), 560 neonates in Uganda were randomly allocated 1:1 to receive BCG-Denmark at birth or at age 6 weeks. The primary outcome was physician-diagnosed non-tuberculous infectious disease. Between birth and age 6 weeks, the BCG-vaccinated children in the early vaccination group had lower incidence (98 presentations) than those in the delayed vaccination group who had not yet received BCG (129 presentations; hazard ratio [HR] 0·71 [95% CI 0·53–0·95], p=0·023).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
